JP Morgan Downgrades Enfusion to Underweight, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Alexei Gogolev has downgraded Enfusion (NYSE:ENFN) from Neutral to Underweight and reduced the price target from $11 to $9.

January 30, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Enfusion downgraded by JP Morgan from Neutral to Underweight with a price target decrease from $11 to $9.
Downgrades by major analysts like JP Morgan can lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The reduction in the price target further suggests a bearish outlook on the stock's value, which can influence market sentiment and trading behavior.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100